Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 70 Guangzhou 64 Fuzhou 40 Chongqing 39 Xiamen 36
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Henan Cancer Hospital75 The First Affiliated Hospital of Zhengzhou University38 Merck Sharp & Dohme LLC28 AbbVie21 Novartis Pharmaceuticals20 Clear sponsor filter
Site location
Beijing70 Guangzhou64 Fuzhou40 Chongqing39 Xiamen36
All 69 locations
Target enrolment
to

Trials with a site in Zhengzhou

28 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1/2
280
Beijing, Fuzhou, Guangzhou, Zhengzhou, Shanghai
2026-05-03
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
60
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Jinan, Hangzhou
2026-03-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
298
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang
2025-07-30
Recruiting
Merck Sharp & Dohme LLC
Phase 2
144
Beijing, Chongqing, Fuzhou, Nanning, Zhengzhou, Nanjing, Shanghai
2025-05-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan
2025-05-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Bengbu, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Wuhan, Xiangyang
2025-03-16
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
180
Hefei, Fuzhou, Xiamen, Guangzhou, Nanning, Zhengzhou, Shanghai, Taiyuan
2024-11-03
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-09-20
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-08-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou
2024-04-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Bengbu, Hefei, Beijing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Beijing, Chongqing, Guangzhou, Guiyang, Haikou, Zhengzhou, Wuhan, Changsha
2023-03-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsNemtabrutinib·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Active, closed
Merck Sharp & Dohme LLC
Phase 1
12
Guangzhou, Zhengzhou, Changsha, Tianjin
2022-06-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou
2022-03-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan
2022-03-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun
2022-01-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Hefei, Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Bengbu, Beijing, Chongging, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou
2021-04-14
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Zhengzhou, Wuhan
2021-04-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-12-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-07-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Heifei, Shanghai, Beijing, Fuzhou Fujian, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2018-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan
2018-12-24
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies with a site in Zhengzhou that also match the filters currently applied.

How many clinical trials are recruiting in Zhengzhou?

14 of the 28 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhengzhou), 28 studies
PhaseStudiesRecruitingShare
Phase 316557.1%
Phase 1/27625%
Phase 23210.7%
Phase 1103.6%
Phase 2/3113.6%

Most active sponsors

Lead sponsors with the most studies (Zhengzhou)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC2814
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.